BPC-157 / TB-500 / KPV

This preparation combines three separately characterized research peptides: BPC-157, a synthetic 15-residue partial sequence of a human gastric-juice protein; TB-500, based on full-length Thymosin Beta-4, a 43-residue actin-binding peptide; and KPV, the C-terminal tripeptide (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Each has a distinct, independently studied profile of model systems and assays, and each is catalogued here on its own terms. No peer-reviewed primary study, review, or registered trial has examined this three-component blend, nor any two-component subset of it; the literature summarized below pertains to the individual components, and no combination or synergy is implied.

The BPC-157 literature centers on connective-tissue and vascular model systems. In tendon-fibroblast work, Chang et al. (2011) used a rat Achilles-tendon explant system and cultured tendon fibroblasts to examine cell outgrowth, transwell migration, and survival under oxidative stress, attributing the observations to the FAK-paxillin pathway; a companion study (Chang et al., 2014) used microarray, PCR, and Western blot to examine growth-hormone-receptor expression in the same cells. Vascular research has examined angiogenesis-associated signaling: Hsieh et al. (2017) used endothelial tube-formation and chick chorioallantoic membrane assays alongside endothelial cell culture to study VEGFR2 expression and the VEGFR2-Akt-eNOS pathway, while a later study (Hsieh et al., 2020) examined the Src-Caveolin-1-eNOS pathway and vasomotor tone. Pharmacokinetic and metabolite-identification work (He et al., 2022; Cox et al., 2017) characterized distribution and in-vitro metabolism in rodent and canine systems and developed analytical detection methods. Review-level syntheses (Sikiric et al., 2011, 2014; Vasireddi et al., 2025; Jozwiak et al., 2025) survey the broader gastrointestinal-cytoprotection and orthopaedic research literature.

TB-500 is based on Thymosin Beta-4, characterized as the principal intracellular G-actin-sequestering peptide. Structural and biochemical work (Xue et al., 2014) used crystallography and exchange assays to examine how the peptide interacts with actin and profilin during actin-filament dynamics, and reviews (Goldstein et al., 2012; Huff et al., 2003) summarize its actin-binding and disorder-to-order behavior. Cardiac model systems have been a recurring context: Bock-Marquette et al. (2004) examined integrin-linked kinase and Akt signaling and cardiomyocyte migration in a coronary-ligation mouse model, and Smart et al. (2007) examined adult epicardial progenitor mobilization and neovascularization; a cardiac-fibroblast study (Kumar and Gupta, 2011) examined oxidative-stress and apoptosis-associated gene expression. Additional reviews (Kleinman and Sosne, 2016) survey dermal research models. Throughout, the cited literature uses full-length Thymosin Beta-4 rather than a truncated fragment — a distinction noted below.

KPV research is concentrated in intestinal-epithelial and immune cell culture and in rodent colitis models. Dalmasso et al. (2008) used Caco2-BBE and HT29 epithelial lines and Jurkat T cells with NF-kB reporter, IkB-alpha degradation, and cytokine-mRNA readouts to examine NF-kB and MAPK signaling, and identified uptake via the PepT1 (SLC15A1) peptide transporter; specificity was probed with a competing dipeptide and receptor-independence with melanocortin-receptor-deficient mice. Murine inflammatory-bowel-disease models (Kannengiesser et al., 2008) and a colitis-associated-cancer model examining PepT1-mediated KPV (2016) extended this work with histology and myeloperoxidase endpoints. Formulation research (Xiao et al., 2017) characterized hyaluronic-acid-functionalized nanoparticle systems for targeted colonic delivery by particle-size and zeta-potential measurements. Reviews (Brzoska et al., 2008, 2010) place KPV among alpha-MSH-derived peptides studied in inflammation research.

Among the three components, full-length Thymosin Beta-4 has been the subject of registered human studies in ophthalmic, dermal, and cardiac research contexts (e.g., NCT00832091, NCT01311518, NCT02597803, NCT05984134); these are referenced only to document that registered studies of a stated design exist, with no claim as to their findings. BPC-157 appears in a registered Phase 1 study (NCT02637284); KPV has no registered human trials. The blend itself has not been the subject of any registered study.

Two points bear on how this literature should be read. First, "TB-500" is a commercial label; the molecule in nearly all primary research is full-length Thymosin Beta-4 (43 residues), whereas the name has historically also referenced a shorter actin-binding fragment. The two are not established as equivalent, and the findings above are attributed to the full-length peptide actually studied. Second, much of the BPC-157 primary literature originates from a limited number of research groups, so independent replication is correspondingly limited. Molecular identifiers for all three components are given in the component profiles and database links below.